RU2409576C2 - Системы, содержащие имидазольное кольцо с заместителями, и способы их получения - Google Patents
Системы, содержащие имидазольное кольцо с заместителями, и способы их получения Download PDFInfo
- Publication number
- RU2409576C2 RU2409576C2 RU2006118033/04A RU2006118033A RU2409576C2 RU 2409576 C2 RU2409576 C2 RU 2409576C2 RU 2006118033/04 A RU2006118033/04 A RU 2006118033/04A RU 2006118033 A RU2006118033 A RU 2006118033A RU 2409576 C2 RU2409576 C2 RU 2409576C2
- Authority
- RU
- Russia
- Prior art keywords
- alkyl
- hydrogen
- salt
- phenyl
- groups
- Prior art date
Links
- 0 *C(*[n]1c2c(C=CC=*=C3)c3nc(N)c2nc1*)=O Chemical compound *C(*[n]1c2c(C=CC=*=C3)c3nc(N)c2nc1*)=O 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D255/00—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00
- C07D255/02—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00 not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Transplantation (AREA)
- Psychiatry (AREA)
- AIDS & HIV (AREA)
- Gastroenterology & Hepatology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Изобретение относится к системам, содержащим имидазольное кольцо, соответствующие веществу формулы (I-1):
в которой: Х представляет собой алкилен, факультативно прерываемый одной или несколькими -О- группами; Z представляет собой -С(O)-; R1-1 выбирается из группы, включающей: водород, алкил, фенил, -N(СН3)(ОСН3), и фенил, замещенный одним или несколькими галогенами; R2 представляет собой водород; алкил; гидроксиалкил; или алкоксиалкил; RA и RB, взятые вместе, образуют слитое фенильное кольцо или к его фармацевтически приемлемым солям. Изобретение также относится к фармацевтическим композициям для индуцирования биосинтеза цитокина, содержащим такие вещества. Указанные вещества могут найти применение в медицине в качестве иммуномодуляторов, для индукции или подавления биосинтеза цитокинов у животных и при лечении заболеваний, в том числе вирусных и злокачественных болезней. 8 н. и 10 з.п. ф-лы.
Description
Claims (18)
1. Вещество, соответствующее формуле (I-1):
в которой X представляет собой алкилен, факультативно прерываемый одной или несколькими -О- группами;
Z представляет собой -С(O)-;
R1-1 выбирается из группы, включающей:
водород,
алкил,
фенил,
-N(СН3)(ОСН3), и
фенил, замещенный одним или несколькими галогенами;
R2 представляет собой водород; алкил; гидроксиалкил; или алкоксиалкил;
RA и RB, взятые вместе, образуют слитое фенильное кольцо или его фармацевтически приемлемая соль.
в которой X представляет собой алкилен, факультативно прерываемый одной или несколькими -О- группами;
Z представляет собой -С(O)-;
R1-1 выбирается из группы, включающей:
водород,
алкил,
фенил,
-N(СН3)(ОСН3), и
фенил, замещенный одним или несколькими галогенами;
R2 представляет собой водород; алкил; гидроксиалкил; или алкоксиалкил;
RA и RB, взятые вместе, образуют слитое фенильное кольцо или его фармацевтически приемлемая соль.
2. Вещество, соответствующее формуле (I-2):
в которой X представляет собой алкилен, факультативно прерываемый одной или
несколькими -О- группами;
n равно 0;
Z представляет собой -С(O)-;
R1-1 выбирается из группы, включающей:
водород,
алкил,
фенил,
-N(СН3)(ОСН3), и
фенил, замещенный одним или несколькими галогенами;
R2 представляет собой водород; алкил; гидроксиалкил; или алкоксиалкил;
или его фармацевтически приемлемая соль.
в которой X представляет собой алкилен, факультативно прерываемый одной или
несколькими -О- группами;
n равно 0;
Z представляет собой -С(O)-;
R1-1 выбирается из группы, включающей:
водород,
алкил,
фенил,
-N(СН3)(ОСН3), и
фенил, замещенный одним или несколькими галогенами;
R2 представляет собой водород; алкил; гидроксиалкил; или алкоксиалкил;
или его фармацевтически приемлемая соль.
3. Вещество, соответствующее формуле (I-3):
в которой Х представляет собой алкилен, факультативно прерываемый одной или несколькими -О- группами;
Z представляет собой -С(O)-, -С(O)O-, или -C(-Q-R1-3)2-;
R1-1 выбирается из группы, включающей:
водород,
алкил,
фенил, и
фенил, замещенный одним или несколькими галогенами;
при условии, что если Z представляет собой -С(O)-, то R1-1 может также быть группой N(СН3)(ОСН3);
при дополнительном условии, что если Z представляет собой - С(O)O-, то R1-1 не является водородом;
при дополнительном условии, что если Z представляет собой - С(O)O-, то Х не включает -О- группы;
Q представляет собой О;
R1-3 представляет собой алкил; и
R2 представляет собой водород; алкил; гидроксиалкил; или алкоксиалкил;
каждая из групп RA' и RB' представляет собой алкил;
или его фармацевтически приемлемая соль.
в которой Х представляет собой алкилен, факультативно прерываемый одной или несколькими -О- группами;
Z представляет собой -С(O)-, -С(O)O-, или -C(-Q-R1-3)2-;
R1-1 выбирается из группы, включающей:
водород,
алкил,
фенил, и
фенил, замещенный одним или несколькими галогенами;
при условии, что если Z представляет собой -С(O)-, то R1-1 может также быть группой N(СН3)(ОСН3);
при дополнительном условии, что если Z представляет собой - С(O)O-, то R1-1 не является водородом;
при дополнительном условии, что если Z представляет собой - С(O)O-, то Х не включает -О- группы;
Q представляет собой О;
R1-3 представляет собой алкил; и
R2 представляет собой водород; алкил; гидроксиалкил; или алкоксиалкил;
каждая из групп RA' и RB' представляет собой алкил;
или его фармацевтически приемлемая соль.
4. Вещество, соответствующее формуле (Ia):
в которой X представляет собой алкилен, факультативно прерываемый одной или несколькими -О- группами;
n равно 0;
R1-1 выбирается из группы, включающей:
водород,
алкил,
фенил,
-N(СН3)(ОСН3), и
фенил, замещенный одним или несколькими галогенами; и
R2 представляет собой водород; алкил; гидроксиалкил; или алкоксиалкил;
или его фармацевтически приемлемая соль.
в которой X представляет собой алкилен, факультативно прерываемый одной или несколькими -О- группами;
n равно 0;
R1-1 выбирается из группы, включающей:
водород,
алкил,
фенил,
-N(СН3)(ОСН3), и
фенил, замещенный одним или несколькими галогенами; и
R2 представляет собой водород; алкил; гидроксиалкил; или алкоксиалкил;
или его фармацевтически приемлемая соль.
5. Вещество, соответствующее формуле (Id):
в которой X представляет собой алкилен, факультативно прерываемый одной или несколькими -О- группами;
n равно 0;
R1-1 выбирается из группы, включающей:
водород и алкил;
Q представляет собой О;
R1-3 представляет собой алкил;
или R1-3 группы могут объединяться друг с другом с образованием насыщенного 5-членного кольца;
R2 представляет собой водород; алкил; гидроксиалкил; или алкоксиалкил;
или его фармацевтически приемлемая соль.
в которой X представляет собой алкилен, факультативно прерываемый одной или несколькими -О- группами;
n равно 0;
R1-1 выбирается из группы, включающей:
водород и алкил;
Q представляет собой О;
R1-3 представляет собой алкил;
или R1-3 группы могут объединяться друг с другом с образованием насыщенного 5-членного кольца;
R2 представляет собой водород; алкил; гидроксиалкил; или алкоксиалкил;
или его фармацевтически приемлемая соль.
7. Вещество по п.3 или его соль, где Z представляет собой - С(O)-.
8. Вещество по п.3 или 5, или его соль, где R1-3 представляет собой алкил или R1-3 группы объединяются друг с другом с образованием 5-членного кольца.
9. Вещество по любому из пп.1-4 и 7, или его соль, где R1-1 выбирается из группы, включающей фенил, алкил и -N(СН3)ОСН3.
10. Вещество по любому из пп.1-4 и 7, или его соль, где R1-1 выбирается из группы, включающей алкил, фенил и водород.
11. Вещество по любому из пп.1-6, или его соль, где Х представляет собой C1-6алкилен или -(CH2)2-4-O-(CH2)1-3-.
12. Вещество по п.11, или его соль, где Х выбирается из группы, включающей -(CH2)1-6-, -СН2-С(СН3)2-, -(СН2)2-O-СН2-, -(CH2)3-О-СН2- и -СН2-С(СН3)2-СН2-.
13. Вещество по любому из пп.1-4 и 7, или его соль, где R1-1 выбирается из группы, включающей алкил и фенил.
14. Вещество по п.13, или его соль, где R1-1 выбирается из группы, включающей метил, этил, н-пропил, изопропил, циклопропил, н-бутил, втор-бутил, изобутил, трет-бутил, н-пентил, циклопентил, н-гексил, циклогексил, фенил, 4-хлорфенил и 2,4-дихлорфенил.
15. Вещество по любому из пп.1-6, или его соль, где R2 выбирается из группы, включающей водород, алкил, гидроксиалкил и алкоксиалкил.
16. Вещество по п.15, или его соль, где R2 выбирается из группы, включающей водород, гидроксиметил, метил; этил, н-пропил, н-бутил, этоксиметил, и 2-метоксиэтил.
17. Фармацевтическая композиция для индуцирования биосинтеза цитокина, содержащая терапевтически эффективное количество вещества по любому из пп.1-6, или его соли в комбинации с фармацевтически приемлемым носителем или наполнителем.
18. Применение вещества по любому из пп.1-6 для производства фармацевтической композиции для индуцирования биосинтеза цитокинов в организме животного.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52496103P | 2003-11-25 | 2003-11-25 | |
US60/524,961 | 2003-11-25 | ||
US58013904P | 2004-06-16 | 2004-06-16 | |
US60/580,139 | 2004-06-16 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2006118033A RU2006118033A (ru) | 2008-01-10 |
RU2409576C2 true RU2409576C2 (ru) | 2011-01-20 |
Family
ID=34636529
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2006118033/04A RU2409576C2 (ru) | 2003-11-25 | 2004-11-24 | Системы, содержащие имидазольное кольцо с заместителями, и способы их получения |
Country Status (15)
Country | Link |
---|---|
US (3) | US8691837B2 (ru) |
EP (1) | EP1687307B1 (ru) |
JP (2) | JP4891088B2 (ru) |
KR (1) | KR101130928B1 (ru) |
AR (1) | AR046781A1 (ru) |
AU (1) | AU2004293078B2 (ru) |
BR (1) | BRPI0416936A (ru) |
CA (1) | CA2547020C (ru) |
IL (2) | IL175915A0 (ru) |
MX (1) | MXPA06005910A (ru) |
MY (1) | MY161812A (ru) |
NZ (1) | NZ547467A (ru) |
RU (1) | RU2409576C2 (ru) |
SG (1) | SG148201A1 (ru) |
WO (1) | WO2005051317A2 (ru) |
Families Citing this family (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6677347B2 (en) * | 2000-12-08 | 2004-01-13 | 3M Innovative Properties Company | Sulfonamido ether substituted imidazoquinolines |
US20040265351A1 (en) | 2003-04-10 | 2004-12-30 | Miller Richard L. | Methods and compositions for enhancing immune response |
EP1617845A4 (en) * | 2003-04-28 | 2006-09-20 | 3M Innovative Properties Co | COMPOSITIONS AND METHODS FOR INDUCING OPOID RECEPTORS |
CA2534313C (en) | 2003-08-05 | 2013-03-19 | 3M Innovative Properties Company | Formulations containing an immune response modifier |
JP2007502293A (ja) * | 2003-08-12 | 2007-02-08 | スリーエム イノベイティブ プロパティズ カンパニー | ヒドロキシルアミン置換イミダゾ含有化合物 |
EP1658076B1 (en) * | 2003-08-27 | 2013-03-06 | 3M Innovative Properties Company | Aryloxy and arylalkyleneoxy substituted imidazoquinolines |
CA2537763A1 (en) * | 2003-09-05 | 2005-03-17 | 3M Innovative Properties Company | Treatment for cd5+ b cell lymphoma |
WO2005079195A2 (en) | 2003-10-03 | 2005-09-01 | 3M Innovative Properties Company | Pyrazolopyridines and analogs thereof |
AR046046A1 (es) | 2003-10-03 | 2005-11-23 | 3M Innovative Properties Co | Imidazoquinolinas alcoxi sustituidas. composiciones farmaceuticas. |
US7544697B2 (en) * | 2003-10-03 | 2009-06-09 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridines and analogs thereof |
US20090075980A1 (en) * | 2003-10-03 | 2009-03-19 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridines and Analogs Thereof |
CA2545774A1 (en) | 2003-11-14 | 2005-06-02 | 3M Innovative Properties Company | Oxime substituted imidazo ring compounds |
CA2545825A1 (en) * | 2003-11-14 | 2005-06-02 | 3M Innovative Properties Company | Hydroxylamine substituted imidazo ring compounds |
BRPI0416936A (pt) | 2003-11-25 | 2007-01-16 | 3M Innovative Properties Co | sistemas de anel de imidazo substituìdos e métodos |
EP1701955A1 (en) * | 2003-12-29 | 2006-09-20 | 3M Innovative Properties Company | Arylalkenyl and arylalkynyl substituted imidazoquinolines |
EP1699788A2 (en) * | 2003-12-30 | 2006-09-13 | 3M Innovative Properties Company | Imidazoquinolinyl, imidazopyridinyl and imidazonaphthyridinyl sulfonamides |
AU2005228150A1 (en) * | 2004-03-24 | 2005-10-13 | 3M Innovative Properties Company | Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines |
WO2005123080A2 (en) * | 2004-06-15 | 2005-12-29 | 3M Innovative Properties Company | Nitrogen-containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines |
WO2006009826A1 (en) * | 2004-06-18 | 2006-01-26 | 3M Innovative Properties Company | Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines |
WO2006065280A2 (en) | 2004-06-18 | 2006-06-22 | 3M Innovative Properties Company | Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods |
WO2006009832A1 (en) * | 2004-06-18 | 2006-01-26 | 3M Innovative Properties Company | Substituted imidazo ring systems and methods |
US8541438B2 (en) * | 2004-06-18 | 2013-09-24 | 3M Innovative Properties Company | Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines |
WO2006038923A2 (en) * | 2004-06-18 | 2006-04-13 | 3M Innovative Properties Company | Aryl substituted imidazonaphthyridines |
US20090270443A1 (en) * | 2004-09-02 | 2009-10-29 | Doris Stoermer | 1-amino imidazo-containing compounds and methods |
WO2006063072A2 (en) * | 2004-12-08 | 2006-06-15 | 3M Innovative Properties Company | Immunomodulatory compositions, combinations and methods |
US8034938B2 (en) | 2004-12-30 | 2011-10-11 | 3M Innovative Properties Company | Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds |
JP5543068B2 (ja) | 2004-12-30 | 2014-07-09 | スリーエム イノベイティブ プロパティズ カンパニー | キラル縮合[1,2]イミダゾ[4,5−c]環状化合物 |
PT1830876E (pt) | 2004-12-30 | 2015-07-13 | Meda Ab | Utilização de imiquimod para o tratamento de metástases cutâneas derivadas de um tumor cancerígeno da mama |
US9248127B2 (en) * | 2005-02-04 | 2016-02-02 | 3M Innovative Properties Company | Aqueous gel formulations containing immune response modifiers |
US20080318998A1 (en) | 2005-02-09 | 2008-12-25 | Coley Pharmaceutical Group, Inc. | Alkyloxy Substituted Thiazoloquinolines and Thiazolonaphthyridines |
US8378102B2 (en) | 2005-02-09 | 2013-02-19 | 3M Innovative Properties Company | Oxime and hydroxylamine substituted thiazolo[4,5-c] ring compounds and methods |
EP1846405A2 (en) | 2005-02-11 | 2007-10-24 | 3M Innovative Properties Company | Oxime and hydroxylamine substituted imidazo 4,5-c ring compounds and methods |
US8658666B2 (en) * | 2005-02-11 | 2014-02-25 | 3M Innovative Properties Company | Substituted imidazoquinolines and imidazonaphthyridines |
JP2008531568A (ja) | 2005-02-23 | 2008-08-14 | コーリー ファーマシューティカル グループ,インコーポレイテッド | ヒドロキシアルキルで置換されたイミダゾナフチリジン |
WO2006091567A2 (en) * | 2005-02-23 | 2006-08-31 | Coley Pharmaceutical Group, Inc. | Hydroxyalkyl substituted imidazoquinoline compounds and methods |
EP1850849A2 (en) * | 2005-02-23 | 2007-11-07 | Coley Pharmaceutical Group, Inc. | Method of preferentially inducing the biosynthesis of interferon |
WO2006098852A2 (en) * | 2005-02-23 | 2006-09-21 | Coley Pharmaceutical Group, Inc. | Hydroxyalkyl substituted imidazoquinolines |
CA2602590A1 (en) | 2005-04-01 | 2006-10-12 | Coley Pharmaceutical Group, Inc. | 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases |
US7943610B2 (en) | 2005-04-01 | 2011-05-17 | 3M Innovative Properties Company | Pyrazolopyridine-1,4-diamines and analogs thereof |
EA200800396A1 (ru) * | 2005-09-02 | 2008-08-29 | Пфайзер Инк. | Гидроксизамещенные 1н-имидазопиридины и способы |
ZA200803029B (en) | 2005-09-09 | 2009-02-25 | Coley Pharm Group Inc | Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods |
AU2006287270A1 (en) * | 2005-09-09 | 2007-03-15 | Coley Pharmaceutical Group, Inc. | Amide and carbamate derivatives of N-{2-[4-amino-2- (ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl}methanesulfonamide and methods |
AU2006292119A1 (en) * | 2005-09-23 | 2007-03-29 | 3M Innovative Properties Company | Method for 1H-imidazo[4,5-c]pyridines and analogs thereof |
KR20080083270A (ko) | 2005-11-04 | 2008-09-17 | 콜레이 파마시티컬 그룹, 인코포레이티드 | 하이드록시 및 알콕시 치환된 1에이치 이미다조퀴놀린 및방법 |
CA2640672A1 (en) | 2006-02-17 | 2007-08-23 | Pfizer Limited | 3 -deazapurine derivatives as tlr7 modulators |
WO2007100634A2 (en) | 2006-02-22 | 2007-09-07 | 3M Innovative Properties Company | Immune response modifier conjugates |
WO2007106854A2 (en) * | 2006-03-15 | 2007-09-20 | Coley Pharmaceutical Group, Inc. | Hydroxy and alkoxy substituted 1h-imidazonaphthyridines and methods |
WO2008008432A2 (en) | 2006-07-12 | 2008-01-17 | Coley Pharmaceutical Group, Inc. | Substituted chiral fused( 1,2) imidazo (4,5-c) ring compounds and methods |
WO2008030511A2 (en) * | 2006-09-06 | 2008-03-13 | Coley Pharmaceuticial Group, Inc. | Substituted 3,4,6,7-tetrahydro-5h, 1,2a,4a,8-tetraazacyclopenta[cd]phenalenes |
US20080149123A1 (en) | 2006-12-22 | 2008-06-26 | Mckay William D | Particulate material dispensing hairbrush with combination bristles |
ES2943385T3 (es) * | 2010-08-17 | 2023-06-12 | 3M Innovative Properties Company | Compuesto modificador de la respuesta inmunitaria lipidada y su uso médico |
MX355623B (es) | 2011-06-03 | 2018-04-25 | 3M Innovative Properties Co | Hidrazino-1h-imidazoquinolin-4-aminas y conjugados elaborados a partir de las mismas. |
US9475804B2 (en) | 2011-06-03 | 2016-10-25 | 3M Innovative Properties Company | Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom |
PT2941233T (pt) | 2013-01-07 | 2020-11-13 | Univ Pennsylvania | Composições e métodos para tratar linfoma cutâneo de células t |
EP3080112B1 (en) * | 2013-12-09 | 2020-06-03 | UCB Biopharma SRL | Imidazopyridine derivatives as modulators of tnf activity |
WO2016183371A1 (en) | 2015-05-13 | 2016-11-17 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Methods for the treatment or prevention of ischemic tissue damage |
JP6956071B2 (ja) | 2015-08-31 | 2021-10-27 | スリーエム イノベイティブ プロパティズ カンパニー | 置換グアニジン基を含有するイミダゾ[4,5−c]環状化合物 |
WO2017040233A1 (en) | 2015-08-31 | 2017-03-09 | 3M Innovative Properties Company | GUANIDINE SUBSTITUTED IMIDAZO[4,5-c] RING COMPOUNDS |
WO2017184735A1 (en) * | 2016-04-19 | 2017-10-26 | Ifm Therapeutics, Inc | Nlrp3 modulators |
EP3445761A1 (en) | 2016-04-19 | 2019-02-27 | Innate Tumor Immunity, Inc. | Nlrp3 modulators |
CA3034553A1 (en) | 2016-08-26 | 2018-03-01 | 3M Innovative Properties Company | Fused [1,2]imidazo[4,5-c] ring compounds substituted with guanidino groups |
TWI674261B (zh) | 2017-02-17 | 2019-10-11 | 美商英能腫瘤免疫股份有限公司 | Nlrp3 調節劑 |
US10766896B2 (en) | 2017-03-01 | 2020-09-08 | 3M Innovative Properties Company | Imidazo[4,5-c] ring compounds containing guanidine substituted benzamide groups |
EP3728255B1 (en) | 2017-12-20 | 2022-01-26 | 3M Innovative Properties Company | Amide substituted imidazo[4,5-c]quinoline compounds with a branched chain linking group for use as an immune response modifier |
EP3759107A1 (en) | 2018-02-28 | 2021-01-06 | 3M Innovative Properties Company | Substituted imidazo[4,5-c]quinoline compounds with an n-1 branched group |
WO2019166946A1 (en) | 2018-02-28 | 2019-09-06 | Pfizer Inc. | Il-15 variants and uses thereof |
AU2019274654B2 (en) | 2018-05-23 | 2023-07-20 | Pfizer Inc. | Antibodies specific for CD3 and uses thereof |
KR20230146098A (ko) | 2018-05-23 | 2023-10-18 | 화이자 인코포레이티드 | GUCY2c에 특이적인 항체 및 이의 용도 |
EP3802536B1 (en) | 2018-05-24 | 2022-07-13 | 3M Innovative Properties Company | N-1 branched cycloalkyl substituted imidazo[4,5-c]quinoline compounds, compositions, and methods |
CN113166143B (zh) | 2018-11-26 | 2024-06-04 | 舒万诺知识产权公司 | N-1支链烷基醚取代的咪唑并[4,5-c]喹啉化合物、组合物和方法 |
WO2020128893A1 (en) | 2018-12-21 | 2020-06-25 | Pfizer Inc. | Combination treatments of cancer comprising a tlr agonist |
CN113924297A (zh) | 2019-06-06 | 2022-01-11 | 3M创新有限公司 | N-1支链烷基取代的咪唑并[4,5-c]喹啉化合物、组合物和方法 |
WO2020250089A1 (en) | 2019-06-12 | 2020-12-17 | 3M Innovative Properties Company | Phenethyl substituted imidazo[4,5-c]quinoline compounds with an n-1 branched group |
MX2022006578A (es) | 2019-12-17 | 2022-07-04 | Pfizer | Anticuerpos especificos para cd47, pd-l1 y sus usos. |
CN115916342A (zh) * | 2020-07-08 | 2023-04-04 | 普渡研究基金会 | 用于治疗纤维化疾病和癌症的化合物、组合物和方法 |
CN116323668A (zh) | 2020-07-17 | 2023-06-23 | 辉瑞公司 | 治疗性抗体及其用途 |
WO2023034341A1 (en) * | 2021-08-30 | 2023-03-09 | Purdue Research Foundation | Conjugates, compositions, and methods for rejuvenation of car t-cells |
Family Cites Families (365)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3314941A (en) * | 1964-06-23 | 1967-04-18 | American Cyanamid Co | Novel substituted pyridodiazepins |
US3412093A (en) * | 1965-12-21 | 1968-11-19 | Delmar Chem | New adenine derivatives and method for their preparation |
DE1645976A1 (de) | 1966-06-18 | 1971-01-21 | Ajinomoto Kk | Verfahren zur Herstellung von Adenosin und 2',3'-O-Isopropylidenadenosin |
ZA704419B (en) | 1969-07-21 | 1971-04-28 | Ici Australia Ltd | Injectable aqueous solutions of tetramisole |
US3866508A (en) * | 1970-09-21 | 1975-02-18 | Elmer F Huslig | Stick for playing percussion instruments |
US3692907A (en) | 1970-10-27 | 1972-09-19 | Richardson Merrell Inc | Treating viral infections with bis-basic ethers and thioethers of fluorenone and fluorene and pharmaceutical compositons of the same |
US3917624A (en) | 1972-09-27 | 1975-11-04 | Pfizer | Process for producing 2-amino-nicotinonitrile intermediates |
US4006237A (en) * | 1973-10-11 | 1977-02-01 | Beecham Group Limited | Tetrahydrocarbostyril derivatives for the prophylaxis of asthma, hayfever and rhinitis |
US3891660A (en) | 1974-02-07 | 1975-06-24 | Squibb & Sons Inc | Derivatives of 1H-imidazo{8 4,5-c{9 pyridine-7-carboxylic acids and esters |
US3899508A (en) | 1974-04-12 | 1975-08-12 | Lilly Co Eli | 5-(2-Aminophenyl)pyrazole-3-carboxylic acids and esters thereof |
DE2423389A1 (de) | 1974-05-14 | 1975-12-04 | Hoechst Ag | Arzneimittel mit psychotroper wirkung und verfahren zu ihrer herstellung |
JPS6016438B2 (ja) | 1976-10-14 | 1985-04-25 | ウェルファイド株式会社 | イミダゾキノリン誘導体 |
US4381344A (en) * | 1980-04-25 | 1983-04-26 | Burroughs Wellcome Co. | Process for producing deoxyribosides using bacterial phosphorylase |
DE3204126A1 (de) | 1982-02-06 | 1983-08-11 | Bayer Ag, 5090 Leverkusen | Pyrazoloxazine, -thiazine, -chinoline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
US4758574A (en) | 1982-05-03 | 1988-07-19 | Eli Lilly And Company | 2-phenylimidazio (4,5-c) pyridines |
US4563525A (en) * | 1983-05-31 | 1986-01-07 | Ici Americas Inc. | Process for preparing pyrazolopyridine compounds |
CA1271477A (en) | 1983-11-18 | 1990-07-10 | John F. Gerster | 1h-imidazo[4,5-c]quinolin-4-amines |
IL73534A (en) | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
ZA848968B (en) | 1983-11-18 | 1986-06-25 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinolines and 1h-imidazo(4,5-c)quinolin-4-amines |
JPS61112075A (ja) | 1984-11-05 | 1986-05-30 | Shionogi & Co Ltd | チエニルピラゾロキノリン誘導体 |
US4593821A (en) | 1985-04-25 | 1986-06-10 | Laros Equipment Company, Inc. | Belt separator for blow molding parts |
US4668686A (en) | 1985-04-25 | 1987-05-26 | Bristol-Myers Company | Imidazoquinoline antithrombrogenic cardiotonic agents |
US4698346A (en) | 1985-05-08 | 1987-10-06 | Usv Pharmaceutical Corporation | Thiazolo[5,4-h]quinoline compounds useful as anti-allergy agents |
US4826830A (en) | 1985-07-31 | 1989-05-02 | Jui Han | Topical application of glyciphosphoramide |
CA1306260C (en) | 1985-10-18 | 1992-08-11 | Shionogi & Co., Ltd. | Condensed imidazopyridine derivatives |
HU197019B (en) * | 1985-11-12 | 1989-02-28 | Egyt Gyogyszervegyeszeti Gyar | Process for producing thiqzolo (4,5-c) quinoline derivatives and pharmaceuticals comprising same |
US4837378A (en) | 1986-01-15 | 1989-06-06 | Curatek Pharmaceuticals, Inc. | Topical metronidazole formulations and therapeutic uses thereof |
JPS6310787A (ja) | 1986-03-06 | 1988-01-18 | Takeda Chem Ind Ltd | ヌクレオシド類縁体、その製造法および抗ウイルス剤 |
US4775674A (en) | 1986-05-23 | 1988-10-04 | Bristol-Myers Company | Imidazoquinolinylether derivatives useful as phosphodiesterase and blood aggregation inhibitors |
CA1287061C (en) * | 1986-06-27 | 1991-07-30 | Roche Holding Ltd. | Pyridine ethanolamine derivatives |
US5500228A (en) * | 1987-05-26 | 1996-03-19 | American Cyanamid Company | Phase separation-microencapsulated pharmaceuticals compositions useful for alleviating dental disease |
US4880779A (en) | 1987-07-31 | 1989-11-14 | Research Corporation Technologies, Inc. | Method of prevention or treatment of AIDS by inhibition of human immunodeficiency virus |
US4774339A (en) | 1987-08-10 | 1988-09-27 | Molecular Probes, Inc. | Chemically reactive dipyrrometheneboron difluoride dyes |
US5536743A (en) | 1988-01-15 | 1996-07-16 | Curatek Pharmaceuticals Limited Partnership | Intravaginal treatment of vaginal infections with buffered metronidazole compositions |
US5225183A (en) | 1988-12-06 | 1993-07-06 | Riker Laboratories, Inc. | Medicinal aerosol formulations |
US5238944A (en) | 1988-12-15 | 1993-08-24 | Riker Laboratories, Inc. | Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine |
US5736553A (en) * | 1988-12-15 | 1998-04-07 | Riker Laboratories, Inc. | Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo 4,5-C!quinolin-4-amine |
US5756747A (en) | 1989-02-27 | 1998-05-26 | Riker Laboratories, Inc. | 1H-imidazo 4,5-c!quinolin-4-amines |
DK0385630T3 (da) * | 1989-02-27 | 1997-05-12 | Riker Laboratories Inc | 1H-imidazo(4,5-c)quinolin-4-aminer som antivirale midler |
US5457183A (en) | 1989-03-06 | 1995-10-10 | Board Of Regents, The University Of Texas System | Hydroxylated texaphyrins |
US5037986A (en) | 1989-03-23 | 1991-08-06 | Minnesota Mining And Manufacturing Company | Olefinic 1H-imidazo[4,5-c]quinolin-4-amines |
US4929624A (en) * | 1989-03-23 | 1990-05-29 | Minnesota Mining And Manufacturing Company | Olefinic 1H-imidazo(4,5-c)quinolin-4-amines |
NZ232740A (en) | 1989-04-20 | 1992-06-25 | Riker Laboratories Inc | Solution for parenteral administration comprising a 1h-imidazo(4,5-c) quinolin-4-amine derivative, an acid and a tonicity adjuster |
US4988815A (en) | 1989-10-26 | 1991-01-29 | Riker Laboratories, Inc. | 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines |
WO1991006682A1 (de) | 1989-11-02 | 1991-05-16 | Pfeifer & Langen | Verfahren und vorrichtung zur verhinderung der krustenbildung in kontinuierlich arbeitenden zucker-kristallisationsapparaten |
US5750134A (en) | 1989-11-03 | 1998-05-12 | Riker Laboratories, Inc. | Bioadhesive composition and patch |
CA2071897A1 (en) | 1989-12-28 | 1991-06-29 | Richard A. Glennon | Sigma receptor ligands and the use thereof |
US5274113A (en) | 1991-11-01 | 1993-12-28 | Molecular Probes, Inc. | Long wavelength chemically reactive dipyrrometheneboron difluoride dyes and conjugates |
US5530114A (en) | 1990-04-30 | 1996-06-25 | Isis Pharmaceuticals, Inc. | Oligonucleotide modulation of arachidonic acid metabolism |
EP0461040A1 (fr) | 1990-06-08 | 1991-12-11 | Roussel Uclaf | Dérivés de l'imidazole, leur procédé de préparation, les intermédiaires obtenus, leur application à titre de médicaments et les compositions pharmaceutiques les renfermant |
CA2093132C (en) | 1990-10-05 | 2002-02-26 | John F. Gerster | Process for the preparation of imidazo[4,5-c]quinolin-4-amines |
MX9203481A (es) | 1990-10-18 | 1992-07-01 | Minnesota Mining & Mfg | Formulaciones. |
US5248782A (en) | 1990-12-18 | 1993-09-28 | Molecular Probes, Inc. | Long wavelength heteroaryl-substituted dipyrrometheneboron difluoride dyes |
SG70625A1 (en) | 1991-03-01 | 2000-02-22 | Minnesota Mining & Mfg | 1-Substituted 2-substituted 1H-imidazo(4, 5-c) quinolin-4-amines |
US5175296A (en) | 1991-03-01 | 1992-12-29 | Minnesota Mining And Manufacturing Company | Imidazo[4,5-c]quinolin-4-amines and processes for their preparation |
US5389640A (en) * | 1991-03-01 | 1995-02-14 | Minnesota Mining And Manufacturing Company | 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
US5342784A (en) | 1991-04-12 | 1994-08-30 | Mitsubishi Paper Mills Limited | Electrophotographic lithographic printing plate |
JPH04327587A (ja) | 1991-04-26 | 1992-11-17 | Asahi Chem Ind Co Ltd | 6’−c−アルキル−3−デアザネプラノシンa誘導体、その製造法およびその用途 |
US5187288A (en) * | 1991-05-22 | 1993-02-16 | Molecular Probes, Inc. | Ethenyl-substituted dipyrrometheneboron difluoride dyes and their synthesis |
US5268376A (en) | 1991-09-04 | 1993-12-07 | Minnesota Mining And Manufacturing Company | 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
TW300219B (ru) | 1991-09-14 | 1997-03-11 | Hoechst Ag | |
PH31245A (en) | 1991-10-30 | 1998-06-18 | Janssen Pharmaceutica Nv | 1,3-Dihydro-2H-imidazoÄ4,5-BÜ-quinolin-2-one derivatives. |
US5266575A (en) | 1991-11-06 | 1993-11-30 | Minnesota Mining And Manufacturing Company | 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines |
US5378848A (en) | 1992-02-12 | 1995-01-03 | Shionogi & Co., Ltd. | Condensed imidazopyridine derivatives |
IL105325A (en) | 1992-04-16 | 1996-11-14 | Minnesota Mining & Mfg | Immunogen/vaccine adjuvant composition |
WO1993023011A1 (en) | 1992-05-18 | 1993-11-25 | Minnesota Mining And Manufacturing Company | Transmucosal drug delivery device |
US5352680A (en) | 1992-07-15 | 1994-10-04 | Regents Of The University Of Minnesota | Delta opioid receptor antagonists to block opioid agonist tolerance and dependence |
US6608201B2 (en) | 1992-08-28 | 2003-08-19 | 3M Innovative Properties Company | Process for preparing 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
TW251284B (ru) | 1992-11-02 | 1995-07-11 | Pfizer | |
US5395937A (en) * | 1993-01-29 | 1995-03-07 | Minnesota Mining And Manufacturing Company | Process for preparing quinoline amines |
WO1994021229A1 (en) | 1993-03-17 | 1994-09-29 | Minnesota Mining And Manufacturing Company | Aerosol formulation containing an ester-, amide-, or mercaptoester-derived dispersing aid |
DE4309969A1 (de) | 1993-03-26 | 1994-09-29 | Bayer Ag | Substituierte heteroanellierte Imidazole |
DE69314318T2 (de) | 1993-04-27 | 1998-04-09 | Agfa Gevaert Nv | Verfahren zum Einfügen von einer Wasserumlöslichen Verbindung in eine hydrophile Schicht |
AU681687B2 (en) | 1993-07-15 | 1997-09-04 | Minnesota Mining And Manufacturing Company | Imidazo(4,5-c)pyridin-4-amines |
US5648516A (en) | 1994-07-20 | 1997-07-15 | Minnesota Mining And Manufacturing Company | Fused cycloalkylimidazopyridines |
US5352784A (en) | 1993-07-15 | 1994-10-04 | Minnesota Mining And Manufacturing Company | Fused cycloalkylimidazopyridines |
CA2131680C (en) | 1993-09-17 | 2006-11-07 | Gerhard Stucky | Process for preparing imidazopyridine derivatives |
US5837809A (en) | 1995-08-11 | 1998-11-17 | Oregon Health Sciences University | Mammalian opioid receptor ligand and uses |
JPH07163368A (ja) * | 1993-12-15 | 1995-06-27 | Hayashibara Biochem Lab Inc | 組換えdnaとその組換えdnaを含む形質転換体 |
TW530047B (en) | 1994-06-08 | 2003-05-01 | Pfizer | Corticotropin releasing factor antagonists |
US6110923A (en) | 1994-06-22 | 2000-08-29 | Biochem Pharma Inc. | Method for treating cancer using novel substituted purinyl derivatives with immunomodulating activity |
US6207646B1 (en) * | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
ATE420171T1 (de) * | 1994-07-15 | 2009-01-15 | Univ Iowa Res Found | Immunomodulatorische oligonukleotide |
US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US5612377A (en) * | 1994-08-04 | 1997-03-18 | Minnesota Mining And Manufacturing Company | Method of inhibiting leukotriene biosynthesis |
US5644063A (en) | 1994-09-08 | 1997-07-01 | Minnesota Mining And Manufacturing Company | Imidazo[4,5-c]pyridin-4-amine intermediates |
GB9420168D0 (en) | 1994-10-06 | 1994-11-23 | Boots Co Plc | Therapeutic agents |
US5571819A (en) | 1994-11-22 | 1996-11-05 | Sabb; Annmarie L. | Imidazopyridines as muscarinic agents |
US5482936A (en) * | 1995-01-12 | 1996-01-09 | Minnesota Mining And Manufacturing Company | Imidazo[4,5-C]quinoline amines |
US6071949A (en) | 1995-03-14 | 2000-06-06 | The United States Of America As Represented By The Department Of Health And Human Services | Use of lipoxygenase inhibitors as anti-cancer therapeutic and intervention agents |
US5585612A (en) | 1995-03-20 | 1996-12-17 | Harp Enterprises, Inc. | Method and apparatus for voting |
FR2732605B1 (fr) | 1995-04-07 | 1997-05-16 | Pasteur Merieux Serums Vacc | Composition destinee a l'induction d'une reponse immunitaire mucosale |
US5766789A (en) | 1995-09-29 | 1998-06-16 | Energetics Systems Corporation | Electrical energy devices |
ATE243697T1 (de) | 1995-12-08 | 2003-07-15 | Pfizer | Substitutierte heterozyclische derivate als crf antagonisten |
JPH09176116A (ja) | 1995-12-27 | 1997-07-08 | Toray Ind Inc | 複素環誘導体およびその医薬用途 |
JPH09208584A (ja) | 1996-01-29 | 1997-08-12 | Terumo Corp | アミド誘導体、およびそれを含有する医薬製剤、および合成中間体 |
US5939047A (en) | 1996-04-16 | 1999-08-17 | Jernberg; Gary R. | Local delivery of chemotherapeutic agents for treatment of periodontal disease |
US5861268A (en) * | 1996-05-23 | 1999-01-19 | Biomide Investment Limited Partnership | Method for induction of tumor cell apoptosis with chemical inhibitors targeted to 12-lipoxygenase |
US5693811A (en) | 1996-06-21 | 1997-12-02 | Minnesota Mining And Manufacturing Company | Process for preparing tetrahdroimidazoquinolinamines |
US5741908A (en) | 1996-06-21 | 1998-04-21 | Minnesota Mining And Manufacturing Company | Process for reparing imidazoquinolinamines |
NZ329798A (en) * | 1996-07-03 | 1999-04-29 | Japan Energy Corp | Purine derivatives their tautomers and salts thereof and interferon secretion inducers, antiviral agents and anticancer drugs containing the same |
US6387938B1 (en) | 1996-07-05 | 2002-05-14 | Mochida Pharmaceutical Co., Ltd. | Benzimidazole derivatives |
US5955299A (en) | 1996-09-27 | 1999-09-21 | Incyte Pharmaceuticals, Inc. | snRNP Sm proteins |
ES2290969T3 (es) | 1996-10-25 | 2008-02-16 | Minnesota Mining And Manufacturing Company | Compuestos modificadores de la respuesta inmune para el tratamiento de enfermedades mediadas por th2 y relacionadas. |
US5939090A (en) * | 1996-12-03 | 1999-08-17 | 3M Innovative Properties Company | Gel formulations for topical drug delivery |
EP0894797A4 (en) | 1997-01-09 | 2001-08-16 | Terumo Corp | NEW AMID DERIVATIVES AND INTERMEDIATES ON YOUR SYNTHESIS |
US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
JPH10298181A (ja) | 1997-04-25 | 1998-11-10 | Sumitomo Pharmaceut Co Ltd | タイプ2ヘルパーt細胞選択的免疫応答抑制剤 |
US6426334B1 (en) | 1997-04-30 | 2002-07-30 | Hybridon, Inc. | Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal |
ES2279572T3 (es) | 1997-05-07 | 2007-08-16 | Schering Corporation | Proteinas receptoras humanas de tipo toll, reactivos y metodos relacionados. |
US6113918A (en) | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
US6303347B1 (en) | 1997-05-08 | 2001-10-16 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
EP1003531B1 (en) * | 1997-05-20 | 2007-08-22 | Ottawa Health Research Institute | Processes for preparing nucleic acid constructs |
CA2291487A1 (en) | 1997-05-29 | 1998-12-03 | New Zealand Pastoral Agriculture Research Institute Limited | Processes for production of immunoglobulin a in milk |
US6123957A (en) | 1997-07-16 | 2000-09-26 | Jernberg; Gary R. | Delivery of agents and method for regeneration of periodontal tissues |
US6077349A (en) | 1997-08-20 | 2000-06-20 | Sony Corporation | Method and apparatus for manufacturing disc-shaped recording medium |
JPH1180156A (ja) | 1997-09-04 | 1999-03-26 | Hokuriku Seiyaku Co Ltd | 1−(置換アリール)アルキル−1h−イミダゾピリジン−4−アミン誘導体 |
US6309623B1 (en) | 1997-09-29 | 2001-10-30 | Inhale Therapeutic Systems, Inc. | Stabilized preparations for use in metered dose inhalers |
JP2001519351A (ja) | 1997-10-07 | 2001-10-23 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | 中枢神経系障害の処置において有用なジピリドイミダゾール誘導体 |
AU732361B2 (en) | 1997-11-28 | 2001-04-26 | Dainippon Sumitomo Pharma Co., Ltd. | Novel heterocyclic compounds |
US6121323A (en) | 1997-12-03 | 2000-09-19 | 3M Innovative Properties Company | Bishydroxyureas |
UA67760C2 (ru) * | 1997-12-11 | 2004-07-15 | Міннесота Майнінг Енд Мануфакчурінг Компані | Имидазонафтиридины и их применение для индуцирования биосинтеза цитокинов |
TW572758B (en) * | 1997-12-22 | 2004-01-21 | Sumitomo Pharma | Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives |
JPH11222432A (ja) | 1998-02-03 | 1999-08-17 | Terumo Corp | インターフェロンを誘起するアミド誘導体を含有する外用剤 |
US6011253A (en) * | 1998-03-31 | 2000-01-04 | Lucent Technologies Inc. | Methods and apparatus for analyzing polarization mode dispersion of an optical device |
US6114058A (en) | 1998-05-26 | 2000-09-05 | Siemens Westinghouse Power Corporation | Iron aluminide alloy container for solid oxide fuel cells |
US6110929A (en) | 1998-07-28 | 2000-08-29 | 3M Innovative Properties Company | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof |
JP2000119271A (ja) | 1998-08-12 | 2000-04-25 | Hokuriku Seiyaku Co Ltd | 1h―イミダゾピリジン誘導体 |
US5962636A (en) | 1998-08-12 | 1999-10-05 | Amgen Canada Inc. | Peptides capable of modulating inflammatory heart disease |
JP2002526403A (ja) | 1998-10-02 | 2002-08-20 | スリーエム イノベイティブ プロパティズ カンパニー | 粘膜を起点としたデリバリーシステムおよび動物への適用 |
US6518280B2 (en) * | 1998-12-11 | 2003-02-11 | 3M Innovative Properties Company | Imidazonaphthyridines |
US20020058674A1 (en) | 1999-01-08 | 2002-05-16 | Hedenstrom John C. | Systems and methods for treating a mucosal surface |
CZ20012446A3 (cs) | 1999-01-08 | 2002-01-16 | 3M Innovative Properties Company | Farmaceutický prostředek pro léčbu onemocnění sliznice |
US6486168B1 (en) | 1999-01-08 | 2002-11-26 | 3M Innovative Properties Company | Formulations and methods for treatment of mucosal associated conditions with an immune response modifier |
EP1495758A3 (en) | 1999-01-08 | 2005-04-13 | 3M Innovative Properties Company | Formulations and methods for treatment of mucosal associated conditions with an immune response modifier |
US6558951B1 (en) | 1999-02-11 | 2003-05-06 | 3M Innovative Properties Company | Maturation of dendritic cells with immune response modifying compounds |
US6294271B1 (en) | 1999-02-12 | 2001-09-25 | Shin-Etsu Chemical Co., Ltd. | Flip-chip type semiconductor device sealing material and flip-chip type semiconductor device |
JP2000247884A (ja) | 1999-03-01 | 2000-09-12 | Sumitomo Pharmaceut Co Ltd | アラキドン酸誘発皮膚疾患治療剤 |
CA2365916A1 (en) | 1999-04-12 | 2000-10-19 | Lexicon Genetics Incorporated | Novel lipoxygenase proteins and polynucleotides encoding the same |
CA2376634A1 (en) | 1999-06-08 | 2000-12-14 | Aventis Pasteur | Immunostimulant oligonucleotide |
US6573273B1 (en) | 1999-06-10 | 2003-06-03 | 3M Innovative Properties Company | Urea substituted imidazoquinolines |
US6451810B1 (en) | 1999-06-10 | 2002-09-17 | 3M Innovative Properties Company | Amide substituted imidazoquinolines |
US6756382B2 (en) | 1999-06-10 | 2004-06-29 | 3M Innovative Properties Company | Amide substituted imidazoquinolines |
US6331539B1 (en) | 1999-06-10 | 2001-12-18 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
US6541485B1 (en) | 1999-06-10 | 2003-04-01 | 3M Innovative Properties Company | Urea substituted imidazoquinolines |
US6315985B1 (en) | 1999-06-18 | 2001-11-13 | 3M Innovative Properties Company | C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability |
EP2314693A3 (en) | 1999-08-13 | 2012-11-28 | Idera Pharmaceuticals, Inc. | Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides |
US6432989B1 (en) | 1999-08-27 | 2002-08-13 | Pfizer Inc | Use of CRF antagonists to treat circadian rhythm disorders |
CO5271670A1 (es) | 1999-10-29 | 2003-04-30 | Pfizer Prod Inc | Antagonistas del factor de liberacion de corticitropina y composiciones relacionadas |
WO2001032144A1 (en) * | 1999-10-29 | 2001-05-10 | Inhale Therapeutic Systems, Inc. | Dry powder compositions having improved dispersivity |
US6916925B1 (en) | 1999-11-05 | 2005-07-12 | 3M Innovative Properties Co. | Dye labeled imidazoquinoline compounds |
US6376669B1 (en) * | 1999-11-05 | 2002-04-23 | 3M Innovative Properties Company | Dye labeled imidazoquinoline compounds |
US6313156B1 (en) | 1999-12-23 | 2001-11-06 | Icos Corporation | Thiazole compounds as cyclic-AMP-specific phosphodiesterase inhibitors |
DE10001037C1 (de) | 2000-01-13 | 2001-12-13 | Byk Gulden Lomberg Chem Fab | Verfahren und Zwischenprodukte zur Herstellung von Imidazopyridinen |
US20040023870A1 (en) * | 2000-01-21 | 2004-02-05 | Douglas Dedera | Methods of therapy and diagnosis using targeting of cells that express toll-like receptor proteins |
GB0001704D0 (en) * | 2000-01-25 | 2000-03-15 | Glaxo Group Ltd | Protein |
US6692745B2 (en) | 2000-01-28 | 2004-02-17 | Arogenics Pharmaceuticals, Inc. | Compositions and methods for inhibition of HIV-1 infection |
HUP0204474A3 (en) | 2000-02-09 | 2004-07-28 | Hokuriku Pharmaceutical | 1h-imidazopyridine derivatives, pharmaceutical compositions containing them and their use |
JP2003528068A (ja) | 2000-03-17 | 2003-09-24 | コリクサ コーポレイション | 新規両親媒性アルデヒドならびにアジュバントおよび免疫エフェクターとしてのそれらの使用 |
US20010046968A1 (en) | 2000-03-23 | 2001-11-29 | Zagon Ian S. | Opioid growth factor modulates angiogenesis |
US6894060B2 (en) * | 2000-03-30 | 2005-05-17 | 3M Innovative Properties Company | Method for the treatment of dermal lesions caused by envenomation |
JP3481930B2 (ja) | 2000-03-30 | 2003-12-22 | 塩野義製薬株式会社 | 縮合イミダゾピリジン誘導体の新規製造法および新規結晶形 |
DE10020465A1 (de) | 2000-04-26 | 2001-11-08 | Osram Opto Semiconductors Gmbh | Strahlungsemittierendes Halbleiterbauelement mit Lumineszenzkonversionselement |
AU2001264753A1 (en) | 2000-05-19 | 2001-12-03 | Millennium Pharmaceuticals, Inc. | 46638, a putative family member of human lipoxygenase |
DE10029580C1 (de) * | 2000-06-15 | 2002-01-10 | Ferton Holding Sa | Vorrichtung zum Entfernen von Körpersteinen mit einem intrakorporalen Lithotripter |
ES2251500T3 (es) | 2000-07-13 | 2006-05-01 | Alteon, Inc. | Tiazolios e imidazolios sustituidos por cianometilo y tratamientos de desordenes asociados al envejecimiento proteinico. |
US6387383B1 (en) | 2000-08-03 | 2002-05-14 | Dow Pharmaceutical Sciences | Topical low-viscosity gel composition |
US6900016B1 (en) | 2000-09-08 | 2005-05-31 | Applera Corporation | Polymorphisms in known genes associated with inflammatory autoimmune disease, methods of detection and uses thereof |
US20020055517A1 (en) | 2000-09-15 | 2002-05-09 | 3M Innovative Properties Company | Methods for delaying recurrence of herpes virus symptoms |
WO2002022809A2 (en) | 2000-09-15 | 2002-03-21 | Coley Pharmaceutical Gmbh | PROCESS FOR HIGH THROUGHPUT SCREENING OF CpG-BASED IMMUNO-AGONIST/ANTAGONIST |
GB0023008D0 (en) | 2000-09-20 | 2000-11-01 | Glaxo Group Ltd | Improvements in vaccination |
JP2002145777A (ja) | 2000-11-06 | 2002-05-22 | Sumitomo Pharmaceut Co Ltd | アラキドン酸誘発皮膚疾患治療剤 |
CZ20031587A3 (cs) * | 2000-12-07 | 2004-01-14 | Aoyama Seisakusho Co., Ltd. | Způsob vypékání ocelových částí produktu |
UA74852C2 (en) | 2000-12-08 | 2006-02-15 | 3M Innovative Properties Co | Urea-substituted imidazoquinoline ethers |
WO2002046749A2 (en) | 2000-12-08 | 2002-06-13 | 3M Innovative Properties Company | Screening method for identifying compounds that selectively induce interferon alpha |
AU2006216669A1 (en) | 2000-12-08 | 2006-08-31 | 3M Innovative Properties Company | Compositions and methods for targeted delivery of immune response modifiers |
US6677347B2 (en) | 2000-12-08 | 2004-01-13 | 3M Innovative Properties Company | Sulfonamido ether substituted imidazoquinolines |
US6660747B2 (en) | 2000-12-08 | 2003-12-09 | 3M Innovative Properties Company | Amido ether substituted imidazoquinolines |
US6664264B2 (en) | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Thioether substituted imidazoquinolines |
US6660735B2 (en) | 2000-12-08 | 2003-12-09 | 3M Innovative Properties Company | Urea substituted imidazoquinoline ethers |
US6667312B2 (en) | 2000-12-08 | 2003-12-23 | 3M Innovative Properties Company | Thioether substituted imidazoquinolines |
US6545017B1 (en) | 2000-12-08 | 2003-04-08 | 3M Innovative Properties Company | Urea substituted imidazopyridines |
US6677348B2 (en) * | 2000-12-08 | 2004-01-13 | 3M Innovative Properties Company | Aryl ether substituted imidazoquinolines |
UA74593C2 (en) | 2000-12-08 | 2006-01-16 | 3M Innovative Properties Co | Substituted imidazopyridines |
US6664260B2 (en) | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Heterocyclic ether substituted imidazoquinolines |
US6664265B2 (en) | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Amido ether substituted imidazoquinolines |
US20020107262A1 (en) | 2000-12-08 | 2002-08-08 | 3M Innovative Properties Company | Substituted imidazopyridines |
US6525064B1 (en) * | 2000-12-08 | 2003-02-25 | 3M Innovative Properties Company | Sulfonamido substituted imidazopyridines |
US6545016B1 (en) | 2000-12-08 | 2003-04-08 | 3M Innovative Properties Company | Amide substituted imidazopyridines |
US6464654B1 (en) * | 2001-01-22 | 2002-10-15 | Julia S. Montgomery | Massaging shoe device |
KR100455713B1 (ko) | 2001-01-29 | 2004-11-06 | 호남석유화학 주식회사 | 올레핀 중합용 다중핵 메탈로센 촉매 및 이를 이용한중합방법 |
US20020182274A1 (en) * | 2001-03-21 | 2002-12-05 | Kung-Ming Lu | Methods for inhibiting cancer growth, reducing infection and promoting general health with a fermented soy extract |
CN1250548C (zh) | 2001-04-17 | 2006-04-12 | 大日本住友制药株式会社 | 新的腺嘌呤衍生物 |
EP1379552B2 (en) * | 2001-04-20 | 2014-11-19 | The Institute for Systems Biology | Toll-like receptor 5 ligands and methods of use |
US20020193729A1 (en) | 2001-04-20 | 2002-12-19 | Cormier Michel J.N. | Microprojection array immunization patch and method |
US6627639B2 (en) | 2001-04-26 | 2003-09-30 | Wyeth | Uses for indoletetrahydropyridine derivatives of 2,3-dihydro-7H-[1,4]dioxino-[2,3-e]indole |
US7226928B2 (en) | 2001-06-15 | 2007-06-05 | 3M Innovative Properties Company | Methods for the treatment of periodontal disease |
EP1401437A1 (en) | 2001-06-15 | 2004-03-31 | 3M Innovative Properties Company | Immune response modifiers for the treatment of periodontal disease |
US6756399B2 (en) | 2001-06-29 | 2004-06-29 | The United States Of America As Represented By The Department Of Health And Human Services | Use of lipoxygenase inhibitors and PPAR ligands as anti-cancer therapeutic and intervention agents |
US6987187B2 (en) | 2001-07-16 | 2006-01-17 | Shionogi & Co., Ltd. | Process for preparation of amidine derivatives |
WO2003009852A1 (en) | 2001-07-24 | 2003-02-06 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
JP2005501550A (ja) | 2001-08-30 | 2005-01-20 | スリーエム イノベイティブ プロパティズ カンパニー | 免疫反応調整剤分子を用いた形質細胞様樹状細胞を成熟させる方法 |
JP4445262B2 (ja) | 2001-10-09 | 2010-04-07 | アムジェン インコーポレイテッド | 抗炎症剤としてのイミダゾール誘導体 |
WO2003094836A2 (en) | 2001-10-12 | 2003-11-20 | University Of Iowa Research Foundation | Methods and products for enhancing immune responses using imidazoquinoline compounds |
JP2005513021A (ja) * | 2001-11-16 | 2005-05-12 | スリーエム イノベイティブ プロパティズ カンパニー | Irm化合物およびトール様受容体経路に関する方法および組成物 |
EP1455789A4 (en) | 2001-11-17 | 2008-02-13 | Martinez Colon Maria | IMIQUIMOD THERAPIES |
WO2003045929A1 (fr) | 2001-11-26 | 2003-06-05 | Takeda Chemical Industries, Ltd. | Derive bicyclique, procede de production de ce derive et utilisation correspondante |
DE60234376D1 (de) | 2001-11-27 | 2009-12-24 | Anadys Pharmaceuticals Inc | 3-beta-d-ribofuranosylthiazolo(4,5-delta)pyridimin-nucleoside und ihre verwendung |
JP4447914B2 (ja) | 2001-11-29 | 2010-04-07 | スリーエム イノベイティブ プロパティズ カンパニー | 免疫応答調節物質を含む医薬品 |
US6677349B1 (en) | 2001-12-21 | 2004-01-13 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
US6775514B2 (en) | 2002-01-11 | 2004-08-10 | Xerox Corporation | Substrate size monitoring system for use in copier/printers |
US6525028B1 (en) * | 2002-02-04 | 2003-02-25 | Corixa Corporation | Immunoeffector compounds |
US20050281813A1 (en) | 2002-02-14 | 2005-12-22 | Nuvelo, Inc. | Methods of therapy and diagnosis using targeting of cells that express toll-like receptor proteins |
EP1478327B1 (en) | 2002-02-22 | 2015-04-29 | Meda AB | Method of reducing and treating uvb-induced immunosuppression |
US20030185835A1 (en) | 2002-03-19 | 2003-10-02 | Braun Ralph P. | Adjuvant for vaccines |
GB0206461D0 (en) | 2002-03-19 | 2002-05-01 | Glaxo Group Ltd | Improvements in vaccination |
ATE491471T1 (de) | 2002-03-19 | 2011-01-15 | Powderject Res Ltd | Adjuvantien für dns impstoffe basierend auf imidazochinoline |
CA2480775C (en) | 2002-04-04 | 2016-05-31 | Coley Pharmaceutical Gmbh | Immunostimulatory g,u-containing oligoribonucleotides |
GB0207906D0 (en) | 2002-04-05 | 2002-05-15 | 3M Innovative Properties Co | Formoterol and mometasone aerosol formulations |
US20060121460A1 (en) | 2002-04-19 | 2006-06-08 | Yale University | Toll-like receptor 11 |
DE60328676D1 (de) | 2002-04-30 | 2009-09-17 | Unigen Pharmaceuticals Inc | Formulierung eines gemisches aus flavonoiden und flavanen mit freiem b ring als therapeutisches mittel |
GB0211649D0 (en) | 2002-05-21 | 2002-07-03 | Novartis Ag | Organic compounds |
EP1511746A2 (en) | 2002-05-29 | 2005-03-09 | 3M Innovative Properties Company | Process for imidazo[4,5-c]pyridin-4-amines |
CA2488801A1 (en) | 2002-06-07 | 2003-12-18 | 3M Innovative Properties Company | Ether substituted imidazopyridines |
MXPA05000893A (es) * | 2002-07-23 | 2005-09-30 | Biogal Gyogyszergyar | Preparacion de 1h-imidazo[4,5-c]quinolin-4-aminas a traves de compuestos intermedios 1h-imidazo [4,5-c] quinolin-4-ftalimida. |
JP2004060458A (ja) * | 2002-07-25 | 2004-02-26 | Denso Corp | 内燃機関用スタータ |
PL374866A1 (en) * | 2002-07-26 | 2005-11-14 | Teva Gyogyszergyar Zartköruen Muködo Reszvenytarsasag | Preparation of 1h-imidazo [4,5-c] quinolin-4-amines via novel 1h-imidazo [4,5-c] quinolin-4-cyano and 1h-imidazo [4,5-c] quinolin-4-carboxamide intermediates |
ATE488246T1 (de) | 2002-08-15 | 2010-12-15 | 3M Innovative Properties Co | Immunstimulatorische zusammensetzungen und verfahren zur stimulierung einer immunantwort |
EP1542688A4 (en) | 2002-09-26 | 2010-06-02 | 3M Innovative Properties Co | 1H-imidazo dimers |
EP1556053A4 (en) | 2002-10-31 | 2006-04-19 | Amgen Inc | ANTI-INFLAMMATORY AGENTS |
WO2004043913A2 (en) | 2002-11-08 | 2004-05-27 | Trimeris, Inc. | Hetero-substituted benzimidazole compounds and antiviral uses thereof |
WO2004053452A2 (en) | 2002-12-11 | 2004-06-24 | 3M Innovative Properties Company | Assays relating to toll-like receptor activity |
AU2003287324A1 (en) | 2002-12-11 | 2004-06-30 | 3M Innovative Properties Company | Gene expression systems and recombinant cell lines |
US7091214B2 (en) * | 2002-12-20 | 2006-08-15 | 3M Innovative Properties Co. | Aryl substituted Imidazoquinolines |
JP2006512391A (ja) | 2002-12-30 | 2006-04-13 | スリーエム イノベイティブ プロパティズ カンパニー | 組み合わせ免疫賦活薬 |
EP1592302A4 (en) | 2003-02-13 | 2007-04-25 | 3M Innovative Properties Co | METHODS AND COMPOSITIONS ASSOCIATED WITH IMMUNE RESPONSE MODIFIER COMPOUNDS AND TOLL-LIKE RECEPTOR 8 |
JP2006519020A (ja) * | 2003-02-27 | 2006-08-24 | スリーエム イノベイティブ プロパティズ カンパニー | Tlr介在生物活性の選択的調節 |
AU2004218349A1 (en) | 2003-03-04 | 2004-09-16 | 3M Innovative Properties Company | Prophylactic treatment of UV-induced epidermal neoplasia |
MXPA05009488A (es) | 2003-03-07 | 2005-12-14 | 3M Innovative Properties Co | 1-amino 1h-imidazoquinolinas. |
US7163947B2 (en) * | 2003-03-07 | 2007-01-16 | 3M Innovative Properties Company | 1-Amino 1H-imidazoquinolines |
AU2004220465A1 (en) * | 2003-03-13 | 2004-09-23 | 3M Innovative Properties Company | Method of tattoo removal |
CA2518082C (en) | 2003-03-13 | 2013-02-12 | 3M Innovative Properties Company | Methods for diagnosing skin lesions |
JP4891066B2 (ja) | 2003-03-13 | 2012-03-07 | スリーエム イノベイティブ プロパティズ カンパニー | 皮膚の質を改善する方法 |
WO2004087049A2 (en) | 2003-03-25 | 2004-10-14 | 3M Innovative Properties Company | Selective activation of cellular activities mediated through a common toll-like receptor |
US20040192585A1 (en) | 2003-03-25 | 2004-09-30 | 3M Innovative Properties Company | Treatment for basal cell carcinoma |
CA2520124A1 (en) | 2003-03-28 | 2004-10-14 | Chiron Corporation | Use of benzazole compounds for immunopotentiation |
US20040265351A1 (en) | 2003-04-10 | 2004-12-30 | Miller Richard L. | Methods and compositions for enhancing immune response |
CA2521682A1 (en) | 2003-04-10 | 2004-12-16 | 3M Innovative Properties Company | Delivery of immune response modifier compounds using metal-containing particulate support materials |
EP1617845A4 (en) | 2003-04-28 | 2006-09-20 | 3M Innovative Properties Co | COMPOSITIONS AND METHODS FOR INDUCING OPOID RECEPTORS |
US7731967B2 (en) | 2003-04-30 | 2010-06-08 | Novartis Vaccines And Diagnostics, Inc. | Compositions for inducing immune responses |
WO2004110992A2 (en) | 2003-06-06 | 2004-12-23 | 3M Innovative Properties Company | Process for imidazo[4,5-c] pyridin-4-amines |
US6943255B2 (en) | 2003-06-06 | 2005-09-13 | 3M Innovative Properties Company | Process for imidazo[4,5-c]pyridin-4-amines |
BRPI0411514A (pt) | 2003-06-20 | 2006-08-01 | Coley Pharm Gmbh | antagonistas de receptor toll-like de molécula pequena |
MY157827A (en) | 2003-06-27 | 2016-07-29 | 3M Innovative Properties Co | Sulfonamide substituted imidazoquinolines |
US20050106300A1 (en) | 2003-06-30 | 2005-05-19 | Purdue Research Foundation | Method for producing a material having an increased solubility in alcohol |
CA2534042A1 (en) | 2003-07-31 | 2005-02-10 | 3M Innovative Properties Company | Compositions for encapsulation and controlled release |
CA2534313C (en) | 2003-08-05 | 2013-03-19 | 3M Innovative Properties Company | Formulations containing an immune response modifier |
JP2007502293A (ja) | 2003-08-12 | 2007-02-08 | スリーエム イノベイティブ プロパティズ カンパニー | ヒドロキシルアミン置換イミダゾ含有化合物 |
AU2004266657B2 (en) | 2003-08-14 | 2009-07-02 | 3M Innovative Properties Company | Lipid-modified immune response modifiers |
WO2005020912A2 (en) | 2003-08-25 | 2005-03-10 | 3M Innovative Properties Company | Delivery of immune response modifier compounds |
WO2005018574A2 (en) * | 2003-08-25 | 2005-03-03 | 3M Innovative Properties Company | Immunostimulatory combinations and treatments |
EP1658076B1 (en) * | 2003-08-27 | 2013-03-06 | 3M Innovative Properties Company | Aryloxy and arylalkyleneoxy substituted imidazoquinolines |
CN1845736A (zh) | 2003-09-02 | 2006-10-11 | 3M创新有限公司 | 治疗粘膜相关病症的方法 |
CA2537763A1 (en) | 2003-09-05 | 2005-03-17 | 3M Innovative Properties Company | Treatment for cd5+ b cell lymphoma |
BRPI0414045A (pt) * | 2003-09-05 | 2006-10-24 | Anadys Pharmaceuticals Inc | administração de ligantes de tlr7 e pró-medicamentos dos mesmos para tratamento de infecção por vìrus de hepatite c |
GB0321615D0 (en) | 2003-09-15 | 2003-10-15 | Glaxo Group Ltd | Improvements in vaccination |
US20050059072A1 (en) * | 2003-09-17 | 2005-03-17 | 3M Innovative Properties Company | Selective modulation of TLR gene expression |
US7687628B2 (en) | 2003-10-01 | 2010-03-30 | Taro Pharmaceuticals U.S.A., Inc. | Method of preparing 4-amino-1H-imidazo(4,5-c)quinolines and acid addition salts thereof |
US7544697B2 (en) | 2003-10-03 | 2009-06-09 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridines and analogs thereof |
WO2005079195A2 (en) | 2003-10-03 | 2005-09-01 | 3M Innovative Properties Company | Pyrazolopyridines and analogs thereof |
US20090075980A1 (en) * | 2003-10-03 | 2009-03-19 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridines and Analogs Thereof |
AR046046A1 (es) | 2003-10-03 | 2005-11-23 | 3M Innovative Properties Co | Imidazoquinolinas alcoxi sustituidas. composiciones farmaceuticas. |
US20050239733A1 (en) | 2003-10-31 | 2005-10-27 | Coley Pharmaceutical Gmbh | Sequence requirements for inhibitory oligonucleotides |
WO2005041891A2 (en) | 2003-10-31 | 2005-05-12 | 3M Innovative Properties Company | Neutrophil activation by immune response modifier compounds |
ITMI20032121A1 (it) | 2003-11-04 | 2005-05-05 | Dinamite Dipharma Spa In Forma Abbr Eviata Dipharm | Procedimento per la preparazione di imiquimod e suoi intermedi |
CA2545825A1 (en) | 2003-11-14 | 2005-06-02 | 3M Innovative Properties Company | Hydroxylamine substituted imidazo ring compounds |
CA2545774A1 (en) * | 2003-11-14 | 2005-06-02 | 3M Innovative Properties Company | Oxime substituted imidazo ring compounds |
CU23404A1 (es) | 2003-11-19 | 2009-08-04 | Ct Ingenieria Genetica Biotech | Polisacáridos capsulares de neisseria meningitidis como inmunopotenciadores mucosales y formulaciones resultantes |
AR046845A1 (es) | 2003-11-21 | 2005-12-28 | Novartis Ag | Derivados de 1h-imidazo[4,5-c]quinolina para tratamiento de enfermedades dependientes de las proteino-quinasas |
RU2006121646A (ru) | 2003-11-21 | 2008-01-10 | Новартис АГ (CH) | Производные 1h-имидазохинолина в качестве ингибиторов протеинкиназы |
BRPI0416936A (pt) | 2003-11-25 | 2007-01-16 | 3M Innovative Properties Co | sistemas de anel de imidazo substituìdos e métodos |
EP1686992A4 (en) | 2003-11-25 | 2009-11-04 | 3M Innovative Properties Co | HYDROXYLAMINE, AND IMIDAZOQUINOLEINS, AND IMIDAZOPYRIDINES AND IMIDAZONAPHTYRIDINE SUBSTITUTED WITH OXIME |
EP1689361A4 (en) | 2003-12-02 | 2009-06-17 | 3M Innovative Properties Co | THERAPEUTIC COMBINATIONS AND PROCESSES WITH IRM COMPOUNDS |
US20050226878A1 (en) | 2003-12-02 | 2005-10-13 | 3M Innovative Properties Company | Therapeutic combinations and methods including IRM compounds |
WO2005076783A2 (en) | 2003-12-04 | 2005-08-25 | 3M Innovative Properties Company | Sulfone substituted imidazo ring ethers |
US7888349B2 (en) | 2003-12-29 | 2011-02-15 | 3M Innovative Properties Company | Piperazine, [1,4]Diazepane, [1,4]Diazocane, and [1,5]Diazocane fused imidazo ring compounds |
EP1701955A1 (en) * | 2003-12-29 | 2006-09-20 | 3M Innovative Properties Company | Arylalkenyl and arylalkynyl substituted imidazoquinolines |
EP1699398A4 (en) | 2003-12-30 | 2007-10-17 | 3M Innovative Properties Co | IMPROVING THE IMMUNE RESPONSE |
EP1699788A2 (en) * | 2003-12-30 | 2006-09-13 | 3M Innovative Properties Company | Imidazoquinolinyl, imidazopyridinyl and imidazonaphthyridinyl sulfonamides |
US20050158325A1 (en) | 2003-12-30 | 2005-07-21 | 3M Innovative Properties Company | Immunomodulatory combinations |
WO2005089317A2 (en) | 2004-03-15 | 2005-09-29 | 3M Innovative Properties Company | Immune response modifier formulations and methods |
AU2005228150A1 (en) | 2004-03-24 | 2005-10-13 | 3M Innovative Properties Company | Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines |
EP1735010A4 (en) | 2004-04-09 | 2008-08-27 | 3M Innovative Properties Co | METHODS, COMPOSITIONS AND PREPARATIONS FOR ADMINISTRATION OF IMMUNE RESPONSE MODIFIERS (MRI) |
WO2006126981A2 (en) | 2004-04-28 | 2006-11-30 | 3M Innovative Properties Company | Compositions and methods for mucosal vaccination |
US20050267145A1 (en) | 2004-05-28 | 2005-12-01 | Merrill Bryon A | Treatment for lung cancer |
US20080015184A1 (en) * | 2004-06-14 | 2008-01-17 | 3M Innovative Properties Company | Urea Substituted Imidazopyridines, Imidazoquinolines, and Imidazonaphthyridines |
WO2005123080A2 (en) | 2004-06-15 | 2005-12-29 | 3M Innovative Properties Company | Nitrogen-containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines |
WO2006009832A1 (en) | 2004-06-18 | 2006-01-26 | 3M Innovative Properties Company | Substituted imidazo ring systems and methods |
WO2006009826A1 (en) | 2004-06-18 | 2006-01-26 | 3M Innovative Properties Company | Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines |
WO2006093514A2 (en) | 2004-06-18 | 2006-09-08 | 3M Innovative Properties Company | Aryl and arylalkylenyl substituted thiazoloquinolines and thiazolonaphthyridines |
US7884207B2 (en) | 2004-06-18 | 2011-02-08 | 3M Innovative Properties Company | Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines |
WO2006065280A2 (en) | 2004-06-18 | 2006-06-22 | 3M Innovative Properties Company | Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods |
WO2006038923A2 (en) | 2004-06-18 | 2006-04-13 | 3M Innovative Properties Company | Aryl substituted imidazonaphthyridines |
WO2006026470A2 (en) | 2004-08-27 | 2006-03-09 | 3M Innovative Properties Company | Hiv immunostimulatory compositions |
US20060045885A1 (en) | 2004-08-27 | 2006-03-02 | Kedl Ross M | Method of eliciting an immune response against HIV |
AU2005282726B2 (en) | 2004-09-02 | 2011-06-02 | 3M Innovative Properties Company | 1-alkoxy 1H-imidazo ring systems and methods |
WO2006029115A2 (en) | 2004-09-02 | 2006-03-16 | 3M Innovative Properties Company | 2-amino 1h imidazo ring systems and methods |
US20090270443A1 (en) | 2004-09-02 | 2009-10-29 | Doris Stoermer | 1-amino imidazo-containing compounds and methods |
WO2006028451A1 (en) | 2004-09-03 | 2006-03-16 | 3M Innovative Properties Company | 1-amino 1-h-imidazoquinolines |
US20080193468A1 (en) | 2004-09-08 | 2008-08-14 | Children's Medical Center Corporation | Method for Stimulating the Immune Response of Newborns |
CA2580343A1 (en) | 2004-09-14 | 2006-03-23 | Novartis Vaccines And Diagnostics, Inc. | Imidazoquinoline compounds |
EP1804583A4 (en) | 2004-10-08 | 2009-05-20 | 3M Innovative Properties Co | ADJUVANT FOR DNA VACCINE |
WO2006063152A2 (en) | 2004-12-08 | 2006-06-15 | 3M Innovative Properties Company | Immunostimulatory combinations and methods |
WO2006063072A2 (en) | 2004-12-08 | 2006-06-15 | 3M Innovative Properties Company | Immunomodulatory compositions, combinations and methods |
US8080560B2 (en) | 2004-12-17 | 2011-12-20 | 3M Innovative Properties Company | Immune response modifier formulations containing oleic acid and methods |
US8034938B2 (en) | 2004-12-30 | 2011-10-11 | 3M Innovative Properties Company | Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds |
JP5543068B2 (ja) | 2004-12-30 | 2014-07-09 | スリーエム イノベイティブ プロパティズ カンパニー | キラル縮合[1,2]イミダゾ[4,5−c]環状化合物 |
JP2008526757A (ja) | 2004-12-30 | 2008-07-24 | スリーエム イノベイティブ プロパティズ カンパニー | 免疫応答調節剤製剤および方法 |
WO2006073939A2 (en) | 2004-12-30 | 2006-07-13 | Takeda Pharmaceutical Company Limited | 1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-amine ethanesulfonate and 1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-amine methanesulfonate |
US8436176B2 (en) | 2004-12-30 | 2013-05-07 | Medicis Pharmaceutical Corporation | Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine |
PT1830876E (pt) | 2004-12-30 | 2015-07-13 | Meda Ab | Utilização de imiquimod para o tratamento de metástases cutâneas derivadas de um tumor cancerígeno da mama |
EP1848967B1 (en) | 2005-02-02 | 2012-02-08 | Mocon, Inc. | Instrument and method for detecting and reporting the size of leaks in hermetically sealed packaging |
US9248127B2 (en) | 2005-02-04 | 2016-02-02 | 3M Innovative Properties Company | Aqueous gel formulations containing immune response modifiers |
US20080318998A1 (en) | 2005-02-09 | 2008-12-25 | Coley Pharmaceutical Group, Inc. | Alkyloxy Substituted Thiazoloquinolines and Thiazolonaphthyridines |
US8378102B2 (en) | 2005-02-09 | 2013-02-19 | 3M Innovative Properties Company | Oxime and hydroxylamine substituted thiazolo[4,5-c] ring compounds and methods |
EP1846405A2 (en) * | 2005-02-11 | 2007-10-24 | 3M Innovative Properties Company | Oxime and hydroxylamine substituted imidazo 4,5-c ring compounds and methods |
US8093390B2 (en) * | 2005-02-11 | 2012-01-10 | 3M Innovative Properties Company | Substituted fused [1,2]imidazo[4,5-C] ring compounds and methods |
US8658666B2 (en) | 2005-02-11 | 2014-02-25 | 3M Innovative Properties Company | Substituted imidazoquinolines and imidazonaphthyridines |
JP2008531568A (ja) | 2005-02-23 | 2008-08-14 | コーリー ファーマシューティカル グループ,インコーポレイテッド | ヒドロキシアルキルで置換されたイミダゾナフチリジン |
WO2006098852A2 (en) | 2005-02-23 | 2006-09-21 | Coley Pharmaceutical Group, Inc. | Hydroxyalkyl substituted imidazoquinolines |
WO2006091567A2 (en) | 2005-02-23 | 2006-08-31 | Coley Pharmaceutical Group, Inc. | Hydroxyalkyl substituted imidazoquinoline compounds and methods |
EP1850849A2 (en) * | 2005-02-23 | 2007-11-07 | Coley Pharmaceutical Group, Inc. | Method of preferentially inducing the biosynthesis of interferon |
WO2006099275A2 (en) | 2005-03-14 | 2006-09-21 | 3M Innovative Properties Company | Method of treating actinic keratosis |
WO2006107771A2 (en) | 2005-04-01 | 2006-10-12 | Coley Pharmaceutical Group, Inc. | PYRAZOLO[3,4-c]QUINOLINES, PYRAZOLO[3,4-c]NAPHTHYRIDINES, ANALOGS THEREOF, AND METHODS |
EP1863770A4 (en) | 2005-04-01 | 2010-05-05 | Coley Pharm Group Inc | RING CLOSURE AND CORRESPONDING METHODS AND INTERMEDIATE PRODUCTS |
US7943610B2 (en) | 2005-04-01 | 2011-05-17 | 3M Innovative Properties Company | Pyrazolopyridine-1,4-diamines and analogs thereof |
CA2602590A1 (en) | 2005-04-01 | 2006-10-12 | Coley Pharmaceutical Group, Inc. | 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases |
EP1874345B1 (en) | 2005-04-25 | 2012-08-15 | 3M Innovative Properties Company | Immunostimulatory compositions |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
EA200800396A1 (ru) | 2005-09-02 | 2008-08-29 | Пфайзер Инк. | Гидроксизамещенные 1н-имидазопиридины и способы |
AU2006287270A1 (en) | 2005-09-09 | 2007-03-15 | Coley Pharmaceutical Group, Inc. | Amide and carbamate derivatives of N-{2-[4-amino-2- (ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl}methanesulfonamide and methods |
ZA200803029B (en) | 2005-09-09 | 2009-02-25 | Coley Pharm Group Inc | Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods |
US8889154B2 (en) | 2005-09-15 | 2014-11-18 | Medicis Pharmaceutical Corporation | Packaging for 1-(2-methylpropyl)-1H-imidazo[4,5-c] quinolin-4-amine-containing formulation |
AU2006292119A1 (en) | 2005-09-23 | 2007-03-29 | 3M Innovative Properties Company | Method for 1H-imidazo[4,5-c]pyridines and analogs thereof |
KR20080083270A (ko) | 2005-11-04 | 2008-09-17 | 콜레이 파마시티컬 그룹, 인코포레이티드 | 하이드록시 및 알콕시 치환된 1에이치 이미다조퀴놀린 및방법 |
WO2007062043A1 (en) | 2005-11-23 | 2007-05-31 | Coley Pharmaceutical Group Inc. | Method of activating murine toll-like receptor 8 |
WO2007075468A1 (en) | 2005-12-16 | 2007-07-05 | Coley Pharmaceutical Group, Inc. | Substituted imidazoquinolines, imidazonaphthyridines, and imidazopyridines, compositions, and methods |
WO2007079086A1 (en) | 2005-12-28 | 2007-07-12 | Coley Pharmaceutical Group, Inc. | Pyrazoloalkyl substituted imidazo ring compounds and methods |
JP2009522296A (ja) | 2005-12-28 | 2009-06-11 | スリーエム イノベイティブ プロパティズ カンパニー | 皮膚のt細胞リンパ腫の治療 |
WO2007079202A2 (en) | 2005-12-28 | 2007-07-12 | Coley Pharmaceutical Group, Inc. | Treatment for acute lymhoblastic leukemia |
WO2007079169A2 (en) | 2005-12-28 | 2007-07-12 | Coley Pharmaceutical Group, Inc. | Treatment for acute myeloid leukemia |
WO2007079146A1 (en) | 2005-12-28 | 2007-07-12 | Coley Pharmaceutical Group, Inc | Treatment for non-hodgkin's lymphoma |
WO2007079171A2 (en) | 2005-12-28 | 2007-07-12 | Coley Pharmaceutical Group, Inc. | Treatment for hodgkin's lymphoma |
US20090306388A1 (en) | 2006-02-10 | 2009-12-10 | Pfizer Inc. | Method for substituted ih-imidazo[4,5-c] pyridines |
WO2007100634A2 (en) | 2006-02-22 | 2007-09-07 | 3M Innovative Properties Company | Immune response modifier conjugates |
US8088788B2 (en) | 2006-03-15 | 2012-01-03 | 3M Innovative Properties Company | Substituted fused[1,2] imidazo[4,5-c] ring compounds and methods |
WO2007106854A2 (en) | 2006-03-15 | 2007-09-20 | Coley Pharmaceutical Group, Inc. | Hydroxy and alkoxy substituted 1h-imidazonaphthyridines and methods |
WO2007143526A2 (en) | 2006-06-05 | 2007-12-13 | Coley Pharmaceutical Group, Inc. | Substituted tetrahydroimidazonaphthyridines and methods |
US20100028381A1 (en) | 2006-06-19 | 2010-02-04 | 3M Innovative Properties Company | Formulation for delivery of immune response modifiers |
WO2008008432A2 (en) | 2006-07-12 | 2008-01-17 | Coley Pharmaceutical Group, Inc. | Substituted chiral fused( 1,2) imidazo (4,5-c) ring compounds and methods |
CA2659733A1 (en) | 2006-07-31 | 2008-02-07 | 3M Innovative Properties Company | Sterilized topical compositions of 1-(2-methylpropyl)-1h-imidazo[4,5-c]quinolin-4-amine |
WO2008030511A2 (en) | 2006-09-06 | 2008-03-13 | Coley Pharmaceuticial Group, Inc. | Substituted 3,4,6,7-tetrahydro-5h, 1,2a,4a,8-tetraazacyclopenta[cd]phenalenes |
WO2008036312A1 (en) | 2006-09-19 | 2008-03-27 | Coley Pharmaceutical Group, Inc. | Fungicidal methods using immune response modifier compounds |
WO2008045543A1 (en) | 2006-10-13 | 2008-04-17 | Coley Pharmaceutical Group, Inc. | Substituted 4h-imidazo [4, 5, 1-ij] [1, 6] naphthyridine-9-amines and their pharmaceutical use |
US20080149123A1 (en) | 2006-12-22 | 2008-06-26 | Mckay William D | Particulate material dispensing hairbrush with combination bristles |
-
2004
- 2004-11-24 BR BRPI0416936-0A patent/BRPI0416936A/pt not_active IP Right Cessation
- 2004-11-24 AR ARP040104350A patent/AR046781A1/es unknown
- 2004-11-24 WO PCT/US2004/039512 patent/WO2005051317A2/en active Search and Examination
- 2004-11-24 SG SG200808728-0A patent/SG148201A1/en unknown
- 2004-11-24 JP JP2006541697A patent/JP4891088B2/ja not_active Expired - Fee Related
- 2004-11-24 AU AU2004293078A patent/AU2004293078B2/en not_active Ceased
- 2004-11-24 MY MYPI20044861A patent/MY161812A/en unknown
- 2004-11-24 NZ NZ547467A patent/NZ547467A/en not_active IP Right Cessation
- 2004-11-24 KR KR1020067012734A patent/KR101130928B1/ko not_active IP Right Cessation
- 2004-11-24 RU RU2006118033/04A patent/RU2409576C2/ru not_active IP Right Cessation
- 2004-11-24 CA CA2547020A patent/CA2547020C/en not_active Expired - Fee Related
- 2004-11-24 EP EP04812098.4A patent/EP1687307B1/en not_active Not-in-force
- 2004-11-24 MX MXPA06005910A patent/MXPA06005910A/es active IP Right Grant
- 2004-11-24 US US10/595,959 patent/US8691837B2/en not_active Expired - Fee Related
-
2006
- 2006-05-25 IL IL175915A patent/IL175915A0/en not_active IP Right Cessation
-
2011
- 2011-09-26 JP JP2011208755A patent/JP2012006976A/ja not_active Ceased
-
2012
- 2012-03-06 IL IL218494A patent/IL218494A0/en unknown
-
2014
- 2014-03-11 US US14/205,114 patent/US9328110B2/en not_active Expired - Fee Related
-
2016
- 2016-03-14 US US15/068,892 patent/US9765071B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US20140194628A1 (en) | 2014-07-10 |
AU2004293078B2 (en) | 2012-01-19 |
KR20060125818A (ko) | 2006-12-06 |
IL175915A0 (en) | 2006-10-05 |
JP4891088B2 (ja) | 2012-03-07 |
AR046781A1 (es) | 2005-12-21 |
CA2547020C (en) | 2014-03-25 |
US9328110B2 (en) | 2016-05-03 |
JP2012006976A (ja) | 2012-01-12 |
SG148201A1 (en) | 2008-12-31 |
BRPI0416936A (pt) | 2007-01-16 |
KR101130928B1 (ko) | 2012-04-12 |
IL218494A0 (en) | 2012-04-30 |
US8691837B2 (en) | 2014-04-08 |
CA2547020A1 (en) | 2005-06-09 |
WO2005051317A2 (en) | 2005-06-09 |
US20070072893A1 (en) | 2007-03-29 |
MXPA06005910A (es) | 2006-08-23 |
EP1687307A4 (en) | 2009-06-17 |
EP1687307A2 (en) | 2006-08-09 |
NZ547467A (en) | 2010-06-25 |
US9765071B2 (en) | 2017-09-19 |
EP1687307B1 (en) | 2016-01-06 |
RU2006118033A (ru) | 2008-01-10 |
JP2007512370A (ja) | 2007-05-17 |
US20160194322A1 (en) | 2016-07-07 |
WO2005051317A3 (en) | 2006-05-11 |
MY161812A (en) | 2017-05-15 |
AU2004293078A1 (en) | 2005-06-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2409576C2 (ru) | Системы, содержащие имидазольное кольцо с заместителями, и способы их получения | |
RU2495044C2 (ru) | Ингибиторы активности протеинтирозинкиназы | |
RU2397168C2 (ru) | Производные тиофена в качестве ингибиторов снк 1 | |
RU2486181C2 (ru) | Пиримидилциклопентаны как ингибиторы акт-протеинкиназ | |
RU2497807C2 (ru) | Карбазольные соединения и терапевтические применения соединений | |
RU2317294C2 (ru) | (имидазол-1-илметил)пиридазин в качестве блокатора nmda рецептора | |
RU2005110918A (ru) | Органические соединения | |
JP2010504346A5 (ru) | ||
JP2007512370A5 (ru) | ||
RU2005113310A (ru) | Производные n-замещенного-2-оксодигидропиридина | |
RU2007140737A (ru) | Пиразолы | |
PE20080257A1 (es) | Derivados de triazol ii | |
JP2006524660A5 (ru) | ||
AR068846A1 (es) | Compuestos derivados de pirrolo (2,3d)-pirimidina inhibidores de la actividad de pkb, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos como agentes anticancer | |
JP2012523457A5 (ru) | ||
RU2009141185A (ru) | Инсектицидные производные арилизоксазолина | |
WO2004074270A3 (en) | Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same | |
AR079486A1 (es) | Compuestos heterociclicos nitrogenados de oxima, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades proliferativas. | |
RU2008152763A (ru) | Применение агонистов каннабиноидного рецептора в качестве индуцирующих гипотермию лекарственных средств для лечения ишемии | |
JP2011529502A5 (ru) | ||
JP2019500387A5 (ru) | ||
JP2006501201A5 (ru) | ||
CA2553704A1 (en) | Substituted benzimidazoles and their use for inducing apoptosis | |
RU2004118247A (ru) | Бензимидазол-или индоламиноацетонитрильные производные для борьбы с паразитами | |
CA2526026A1 (en) | Furazanobenzimidazoles |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20091001 |
|
FZ9A | Application not withdrawn (correction of the notice of withdrawal) |
Effective date: 20091019 |
|
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20171125 |